PubMed COVID-19 Clinical Care

Molnupiravir: Is It Time to Move In or Move Out?With more than 250 million diagnosed cases and 5 million deaths, Covid-19 is our epoch-defining pandemic - and it is still ongoing. Despite the development of several effective Covid-19 vaccines, there

CONCLUSIONS: This protocol paper offers real-world insights into research methods and practices to identify barriers and facilitators to implementation LM in health systems. Findings can advise LM implementation across various health system contexts

CONCLUSIONS: Vaccination against COVID-19 was associated with a lower but not statistically significantly different risk of death in the first 60 days. These results agree with prior scientific knowledge suggesting vaccination is safe with the

Much has changed since March 2020, when the World Health Organization declared Covid-19 a pandemic and clinicians around the world began desperately searching for therapies that could help afflicted patients. Barely 2.5 years after SARS-CoV-2 was

CONCLUSIONS: The presented findings in wastewater samples are primarily at the genus level and can serve as a preliminary "screening" tool that may serve as indication to initiate further testing for the confirmation of the presence of species that

CONCLUSIONS: COVID-19 mortality disproportionally affected those of lower SES and exacerbated existing social inequalities in Denmark. We conclude that in health emergencies, particular attention should be paid to those who are least socially

Under the threat of the novel coronavirus, people are compelled to contemplate some ultimate existential questions, such as life and death. This study collected texts related to the death psychology from Sina Weibo, and after data cleaning, a total

CONCLUSIONS: Being male was the unique protective factor in both waves. Other factors reflected different medical behaviours and the impact of comorbidities. Evidence of the effect of therapies adds valuable information that may drive future medical

A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label

CONCLUSIONS: The COVID-19 lockdown measures were associated with a heavier birth weight and a higher risk of macrosomia. Early pregnancy periods may be a more susceptible exposure window for a heavier birth weight and a higher risk of macrosomia. We